›Portfolio Companies

Past, Present and Future Leaders

InterWest is proud and privileged to partner with visionary management teams who are shaping the future of Information Technology and Healthcare. The companies they have started are vital parts of the portfolio of industry-leading startups that InterWest has helped over the last four decades.

Healthcare

Gil Kliman

Information Technology

Finance & Administration

Katie Passalacqua

About Interwest

IW Discrimination,
Harassment & Retaliation
Prevention Policy

Contact

467 First Street, Suite 201
Los Altos, CA 94022, USA
T: 650-854-8585
F: 650-854-4706

Early stage IT and Healthcare Investing

Labrys Biologics

portfoliocompanies

company snapshot

Labrys Biologics is a private, venture-financed development stage biotechnology company focused on treatments for chronic migraine. Labrys' lead candidate, LBR-101 (formerly known as RN-307), is an anti-CGRP monoclonal antibody which has completed Phase 1.

website

Leadership

Follow The Company

Back to portfolio companies overview

Investment Team

Recent News1

Anti-CGRP antibodies for migraine turn industry heads August, 2014

Teva to Acquire Labrys Biologics, Inc.: Novel Migraine Prophylaxis Treatment Adds Significant New Dimension to Teva’s Growing Pain Care Franchise June, 2014

Teva buys into a blockbuster migraine drug rivalry with $825M Labrys buyout June, 2014